Nasdaq Global Select Market
AI overview
Sign in and the AI will write an overview from our coverage.
Headlines · 1
- Nvidia-backed AI drug developer Iambic prices IPO at $16 a share
AI drug discovery company Iambic Therapeutics said on Oct. 14 local time that it priced its initial public offering at $16 per share, offering 9.375 million shares to raise an expected $150 million, with underwriters granted a 30-day option for up to 1.40625 million additional shares. The stock is expected to list on the Nasdaq Global Select Market on Oct. 15 under the ticker "IAM," with the offering slated to close Oct. 16; JPMorgan, Jefferies, BofA Securities and Citigroup are joint bookrunners. Iambic uses AI alongside automated chemistry and biology experiments to speed drug development, and its candidate IAM1363 has entered clinical trials; Nvidia was among its backers.
36氪快讯 · 🔥 0
Experience and discussion from the community
Share my Nasdaq Global Select Market experienceAsk about Nasdaq Global Select Market
Nobody has shared their experience with Nasdaq Global Select Market yet.